An Antibody-based Multifaceted Approach Targeting the Human Transferrin Receptor for the Treatment of B-cell Malignancies
- Autores
- Daniels, Tracy R.; Ortiz Sanchez, Elizabeth; Luria Pérez, Rosendo; Quintero, Rafaela; Helguera, Gustavo Fernando; Bonavida, Benjamin; Martinez Maza, Otoniel; Penichet, Manuel L.
- Año de publicación
- 2011
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- We previously developed an antibody-avidin fusion protein (ch128.1Av) targeting the human transferrin receptor 1 (TfR1, also known as CD71), which demonstrates direct in vitro cytotoxicity against malignant hematopoietic cells. This cytotoxicity is attributed to its ability to decrease the level of TfR1 leading to lethal iron deprivation. We now report that ch128.1Av shows the ability to bind the Fc γ receptors and the complement component C1q, suggesting that it is capable of eliciting Fcmediated effector functions such as antibody-dependent cellmediated cytotoxicity and complement-mediated cytotoxicity. In addition, in 2 disseminated multiple myeloma xenograft mouse models, we show that a single dose of ch128.1Av results in significant antitumor activity, including long-term survival. It is interesting to note that the parental antibody without avidin (ch128.1) also shows remarkable in vivo anticancer activity despite its limited in vitro cytotoxicity. Finally, we demonstrate that ch128.1Av is not toxic to pluripotent hematopoietic progenitor cells using the long-term cell-initiating culture assay suggesting that these important progenitors would be preserved in different therapeutic approaches, including the in vitro purging of cancer cells for autologous transplantation and in vivo passive immunotherapy. Our results suggest that ch128.1Av and ch128.1 may be effective in the therapy of human multiple myeloma and potentially other hematopoietic malignancies.
Fil: Daniels, Tracy R.. David Geffen School of Medicine; Estados Unidos
Fil: Ortiz Sanchez, Elizabeth. David Geffen School of Medicine; Estados Unidos. Instituto Nacional de Cancerología; México
Fil: Luria Pérez, Rosendo. David Geffen School of Medicine; Estados Unidos. Hospital Infantil de México "Federico Gómez"; México
Fil: Quintero, Rafaela. David Geffen School of Medicine; Estados Unidos
Fil: Helguera, Gustavo Fernando. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; Argentina. David Geffen School of Medicine; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Bonavida, Benjamin. University of California; Estados Unidos
Fil: Martinez Maza, Otoniel. University of California; Estados Unidos
Fil: Penichet, Manuel L.. David Geffen School of Medicine; Estados Unidos. University of California; Estados Unidos - Materia
-
Transferrin Receptor
Cd71
Antibody Fusion Protein
Cancer - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/12925
Ver los metadatos del registro completo
id |
CONICETDig_120bf6e0e1510126413848b754635e91 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/12925 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
An Antibody-based Multifaceted Approach Targeting the Human Transferrin Receptor for the Treatment of B-cell MalignanciesDaniels, Tracy R.Ortiz Sanchez, ElizabethLuria Pérez, RosendoQuintero, RafaelaHelguera, Gustavo FernandoBonavida, BenjaminMartinez Maza, OtonielPenichet, Manuel L.Transferrin ReceptorCd71Antibody Fusion ProteinCancerhttps://purl.org/becyt/ford/3.4https://purl.org/becyt/ford/3We previously developed an antibody-avidin fusion protein (ch128.1Av) targeting the human transferrin receptor 1 (TfR1, also known as CD71), which demonstrates direct in vitro cytotoxicity against malignant hematopoietic cells. This cytotoxicity is attributed to its ability to decrease the level of TfR1 leading to lethal iron deprivation. We now report that ch128.1Av shows the ability to bind the Fc γ receptors and the complement component C1q, suggesting that it is capable of eliciting Fcmediated effector functions such as antibody-dependent cellmediated cytotoxicity and complement-mediated cytotoxicity. In addition, in 2 disseminated multiple myeloma xenograft mouse models, we show that a single dose of ch128.1Av results in significant antitumor activity, including long-term survival. It is interesting to note that the parental antibody without avidin (ch128.1) also shows remarkable in vivo anticancer activity despite its limited in vitro cytotoxicity. Finally, we demonstrate that ch128.1Av is not toxic to pluripotent hematopoietic progenitor cells using the long-term cell-initiating culture assay suggesting that these important progenitors would be preserved in different therapeutic approaches, including the in vitro purging of cancer cells for autologous transplantation and in vivo passive immunotherapy. Our results suggest that ch128.1Av and ch128.1 may be effective in the therapy of human multiple myeloma and potentially other hematopoietic malignancies.Fil: Daniels, Tracy R.. David Geffen School of Medicine; Estados UnidosFil: Ortiz Sanchez, Elizabeth. David Geffen School of Medicine; Estados Unidos. Instituto Nacional de Cancerología; MéxicoFil: Luria Pérez, Rosendo. David Geffen School of Medicine; Estados Unidos. Hospital Infantil de México "Federico Gómez"; MéxicoFil: Quintero, Rafaela. David Geffen School of Medicine; Estados UnidosFil: Helguera, Gustavo Fernando. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; Argentina. David Geffen School of Medicine; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaFil: Bonavida, Benjamin. University of California; Estados UnidosFil: Martinez Maza, Otoniel. University of California; Estados UnidosFil: Penichet, Manuel L.. David Geffen School of Medicine; Estados Unidos. University of California; Estados UnidosLippincott Williams2011-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/12925Daniels, Tracy R.; Ortiz Sanchez, Elizabeth; Luria Pérez, Rosendo; Quintero, Rafaela; Helguera, Gustavo Fernando; et al.; An Antibody-based Multifaceted Approach Targeting the Human Transferrin Receptor for the Treatment of B-cell Malignancies; Lippincott Williams; Journal Of Immunotherapy; 34; 6; 11-2011; 500-5081524-9557enginfo:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717268/info:eu-repo/semantics/altIdentifier/url/http://journals.lww.com/immunotherapy-journal/pages/articleviewer.aspx?year=2011&issue=07000&article=00004&type=abstractinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:42:50Zoai:ri.conicet.gov.ar:11336/12925instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:42:50.317CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
An Antibody-based Multifaceted Approach Targeting the Human Transferrin Receptor for the Treatment of B-cell Malignancies |
title |
An Antibody-based Multifaceted Approach Targeting the Human Transferrin Receptor for the Treatment of B-cell Malignancies |
spellingShingle |
An Antibody-based Multifaceted Approach Targeting the Human Transferrin Receptor for the Treatment of B-cell Malignancies Daniels, Tracy R. Transferrin Receptor Cd71 Antibody Fusion Protein Cancer |
title_short |
An Antibody-based Multifaceted Approach Targeting the Human Transferrin Receptor for the Treatment of B-cell Malignancies |
title_full |
An Antibody-based Multifaceted Approach Targeting the Human Transferrin Receptor for the Treatment of B-cell Malignancies |
title_fullStr |
An Antibody-based Multifaceted Approach Targeting the Human Transferrin Receptor for the Treatment of B-cell Malignancies |
title_full_unstemmed |
An Antibody-based Multifaceted Approach Targeting the Human Transferrin Receptor for the Treatment of B-cell Malignancies |
title_sort |
An Antibody-based Multifaceted Approach Targeting the Human Transferrin Receptor for the Treatment of B-cell Malignancies |
dc.creator.none.fl_str_mv |
Daniels, Tracy R. Ortiz Sanchez, Elizabeth Luria Pérez, Rosendo Quintero, Rafaela Helguera, Gustavo Fernando Bonavida, Benjamin Martinez Maza, Otoniel Penichet, Manuel L. |
author |
Daniels, Tracy R. |
author_facet |
Daniels, Tracy R. Ortiz Sanchez, Elizabeth Luria Pérez, Rosendo Quintero, Rafaela Helguera, Gustavo Fernando Bonavida, Benjamin Martinez Maza, Otoniel Penichet, Manuel L. |
author_role |
author |
author2 |
Ortiz Sanchez, Elizabeth Luria Pérez, Rosendo Quintero, Rafaela Helguera, Gustavo Fernando Bonavida, Benjamin Martinez Maza, Otoniel Penichet, Manuel L. |
author2_role |
author author author author author author author |
dc.subject.none.fl_str_mv |
Transferrin Receptor Cd71 Antibody Fusion Protein Cancer |
topic |
Transferrin Receptor Cd71 Antibody Fusion Protein Cancer |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.4 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
We previously developed an antibody-avidin fusion protein (ch128.1Av) targeting the human transferrin receptor 1 (TfR1, also known as CD71), which demonstrates direct in vitro cytotoxicity against malignant hematopoietic cells. This cytotoxicity is attributed to its ability to decrease the level of TfR1 leading to lethal iron deprivation. We now report that ch128.1Av shows the ability to bind the Fc γ receptors and the complement component C1q, suggesting that it is capable of eliciting Fcmediated effector functions such as antibody-dependent cellmediated cytotoxicity and complement-mediated cytotoxicity. In addition, in 2 disseminated multiple myeloma xenograft mouse models, we show that a single dose of ch128.1Av results in significant antitumor activity, including long-term survival. It is interesting to note that the parental antibody without avidin (ch128.1) also shows remarkable in vivo anticancer activity despite its limited in vitro cytotoxicity. Finally, we demonstrate that ch128.1Av is not toxic to pluripotent hematopoietic progenitor cells using the long-term cell-initiating culture assay suggesting that these important progenitors would be preserved in different therapeutic approaches, including the in vitro purging of cancer cells for autologous transplantation and in vivo passive immunotherapy. Our results suggest that ch128.1Av and ch128.1 may be effective in the therapy of human multiple myeloma and potentially other hematopoietic malignancies. Fil: Daniels, Tracy R.. David Geffen School of Medicine; Estados Unidos Fil: Ortiz Sanchez, Elizabeth. David Geffen School of Medicine; Estados Unidos. Instituto Nacional de Cancerología; México Fil: Luria Pérez, Rosendo. David Geffen School of Medicine; Estados Unidos. Hospital Infantil de México "Federico Gómez"; México Fil: Quintero, Rafaela. David Geffen School of Medicine; Estados Unidos Fil: Helguera, Gustavo Fernando. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; Argentina. David Geffen School of Medicine; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina Fil: Bonavida, Benjamin. University of California; Estados Unidos Fil: Martinez Maza, Otoniel. University of California; Estados Unidos Fil: Penichet, Manuel L.. David Geffen School of Medicine; Estados Unidos. University of California; Estados Unidos |
description |
We previously developed an antibody-avidin fusion protein (ch128.1Av) targeting the human transferrin receptor 1 (TfR1, also known as CD71), which demonstrates direct in vitro cytotoxicity against malignant hematopoietic cells. This cytotoxicity is attributed to its ability to decrease the level of TfR1 leading to lethal iron deprivation. We now report that ch128.1Av shows the ability to bind the Fc γ receptors and the complement component C1q, suggesting that it is capable of eliciting Fcmediated effector functions such as antibody-dependent cellmediated cytotoxicity and complement-mediated cytotoxicity. In addition, in 2 disseminated multiple myeloma xenograft mouse models, we show that a single dose of ch128.1Av results in significant antitumor activity, including long-term survival. It is interesting to note that the parental antibody without avidin (ch128.1) also shows remarkable in vivo anticancer activity despite its limited in vitro cytotoxicity. Finally, we demonstrate that ch128.1Av is not toxic to pluripotent hematopoietic progenitor cells using the long-term cell-initiating culture assay suggesting that these important progenitors would be preserved in different therapeutic approaches, including the in vitro purging of cancer cells for autologous transplantation and in vivo passive immunotherapy. Our results suggest that ch128.1Av and ch128.1 may be effective in the therapy of human multiple myeloma and potentially other hematopoietic malignancies. |
publishDate |
2011 |
dc.date.none.fl_str_mv |
2011-11 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/12925 Daniels, Tracy R.; Ortiz Sanchez, Elizabeth; Luria Pérez, Rosendo; Quintero, Rafaela; Helguera, Gustavo Fernando; et al.; An Antibody-based Multifaceted Approach Targeting the Human Transferrin Receptor for the Treatment of B-cell Malignancies; Lippincott Williams; Journal Of Immunotherapy; 34; 6; 11-2011; 500-508 1524-9557 |
url |
http://hdl.handle.net/11336/12925 |
identifier_str_mv |
Daniels, Tracy R.; Ortiz Sanchez, Elizabeth; Luria Pérez, Rosendo; Quintero, Rafaela; Helguera, Gustavo Fernando; et al.; An Antibody-based Multifaceted Approach Targeting the Human Transferrin Receptor for the Treatment of B-cell Malignancies; Lippincott Williams; Journal Of Immunotherapy; 34; 6; 11-2011; 500-508 1524-9557 |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717268/ info:eu-repo/semantics/altIdentifier/url/http://journals.lww.com/immunotherapy-journal/pages/articleviewer.aspx?year=2011&issue=07000&article=00004&type=abstract |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Lippincott Williams |
publisher.none.fl_str_mv |
Lippincott Williams |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613348421795840 |
score |
13.070432 |